ANTH Plunges On Failed SOLUTION, All Eyes On CEMP, FDA Says No To AMPH Again

Shares of Anthera Pharmaceuticals Inc. slipped over 58% in extended trading on Tuesday in the wake of its phase III trial of Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency falling short of expectations.

from RTT - Biotech http://ift.tt/2hrNpFH
via IFTTT